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AbstrAct
Introduction Several societies have produced and 
disseminated clinical practice guidelines (CPGs) for the 
symptomatic management of fever in children. However, 
to date, the quality of such guidelines has not been 
appraised.
Objective To identify and evaluate guidelines for the 
symptomatic management of fever in children.
Methods The research was conducted using PubMed, 
guideline websites, and Google (January 2010 to July 
2016). The quality of the CPGs was independently 
assessed by two assessors using the Appraisal of 
Guidelines for Research & Evaluation II (AGREE II) 
instrument, and specific recommendations in guidelines 
were summarised and evaluated. Domain scores were 
considered of sufficient quality when >60% and of good 
quality when >80%.
results Seven guidelines were retrieved. The median 
score for the scope and purpose domain was 85.3% 
(range 66.6–100%). The median score for the stakeholder 
involvement domain was 57.5% (range 33.3–83.3%) 
and four guidelines scored >60%. The median score for 
the rigour of development domain was 52.0% (range 
14.6–98.9%), and only three guidelines scored >60%. 
The median score for the clarity of presentation domain 
was 80.9% (range 50.0–94.4%). The median score for 
the applicability domain was 39.3% (8.3–100%). Only one 
guideline scored >60%. The median score for the editorial 
independence domain was 48.84% (0–91.6%); only three 
guidelines scored >60%.
conclusion Most guidelines were recommended for use 
even if with modification, especially in the methodology, 
the applicability and the editorial independence domains. 
Our results could help improve reporting of future 
guidelines, and affect the selection and use of guidelines 
in clinical practice.
IntrOductIOn
Fever is one of the most common clin-
ical reasons for paediatric consultations, 
accounting for about one-third of all 
presenting conditions in children.1–3
Concerns of parents/tutors/caregivers 
about serious causes of fever (ie, severe 
bacterial infections) and misconceptions 
about fever as a sufficient trigger of brain 
damage have led to the spreading of ‘fever-
phobia’.1 4 5 Several studies have reported a 
high percentage of parents/tutors/caregivers 
administering antipyretics even when there 
is minimal or no fever, with wrong dosages 
or with insufficient intervals between the 
doses.4–6 Fever is a physiologic mechanism 
with beneficial effects in fighting infection 
and it is not associated with long-term neuro-
logic complications.7 The only purpose for 
treating fever in children must be to relieve 
the child’s discomfort and not to lower the 
body temperature.8
The inappropriate management of fever 
may delay the diagnosis and increase the 
risk of antipyretic overdose. Moreover, other 
factors may increase drug toxicity such as the 
alternate/combined use of two antipyretics,9 
the use of rectal formulations,10 and the 
administration of these drugs in the presence 
of contraindicated underlying diseases.11 
Finally, overtreatment may have a significant 
economic impact in low-middle income and 
high income countries.
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Research
strengths and limitation of this study
 ► To the best of our knowledge this is the first 
study to appraise guidelines on the symptomatic 
management of fever with the AGREE II instrument.
 ► Moreover, recommendations dealing with 
symptomatic management of fever have been 
extracted and resumed in comparative tables, 
focusing on possible gaps and common messages 
between the guidelines.
 ► The AGREE methodology does not provide a 
threshold for discrimination between high quality 
and low quality guidelines.
 ► Searching may not have been exhaustive; therefore, 
we cannot exclude the possibility that some 
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In order to rationalise and standardise the symptom-
atic management of fever in children, national health 
agencies and scientific societies have produced and 
disseminated clinical guidelines. It has been demon-
strated that parents/tutors do not fully comply with 
these recommendations, as they used to employ tradi-
tional physical means and administer antipyretics with 
inappropriate indications and posology.3 12–16 Moreover, 
important discrepancies have been reported between the 
practices of healthcare professionals and the recommen-
dations of guidelines.17–19
Several barriers to applying these guidelines in clinical 
practice have been identified.19–22 Thus, we conducted 
this study to identify and evaluate the quality of the inter-
national clinical practice guidelines (CPGs) for the use of 




The primary outcomes of the study were to encourage the 
improvement of the quality of guidelines, to reinforce the 
messages of common recommendations, and to stimulate 
further research on discordant recommendations and 
the issues of international guidelines in order to unify 
medical behaviour.
Guidelines research
The search for guidelines for the symptomatic manage-
ment of fever in children was carried out using 
documents issued by national scientific societies or by 
government organisations between January 2010 and July 
2016 in every language, through the use of appropriate 
keywords and the following search engines: PubMed; 
National Guideline Clearinghouse (www. guideline. gov); 
NICE: National Institute for Health and Care Excellence 
(www. nice. org. uk); Canadian CPG Infobase: Clinical 
Practice Guidelines Database (www. cma. ca/ En/ Pages/ 
clinical- practice- guidelines. aspx); Scottish Intercollegiate 
Guidelines Network (SIGN) (www. sign. ac. uk); Australian 
Clinical Practice Guidelines (http://www. clinicalguide-
lines. gov. au/);%20and Guidelines International Network 
(http://www. g- i- n. net/). Additional research was 
conducted on Google. In this research we used the 
following keywords: ‘guideline’, ‘fever’, ‘children’, and 
‘antipyretics’, (see ‘Search strategy’ in supplementary 
material 1). The search was limited to January 2010 and 
not earlier in order to evaluate only the most recent and 
updated guidelines.
exclusion criteria
Guidelines that did not focus on the management of fever 
as a symptom/sign, or were not original or were issued 
on a regional level, were excluded, as well as any docu-
ments that were not guidelines (such as position papers 
and reviews).
Quality evaluation
Two assessors, one with experience in developing and 
evaluating guidelines (EC) and another assessor (BB), 
used the online training tools recommended by the 
AGREE collaboration before conducting appraisals.23 
They independently evaluated the included guidelines 
using the AGREE II instrument,23 which consists of a total 
of 23 items in six domains: ‘Scope and purpose’, ‘Stake-
holder involvement’, ‘Rigour of development’, ‘Clarity 
of presentation’, ‘Applicability’, and ‘Editorial indepen-
dence’. Each item was rated on a seven-point scale from 1 
(strongly disagree) to 7 (strongly agree). A scaled domain 
percentage score was calculated, according to the AGREE 
II methodology,23 as follows: (obtained score−minimum 
possible score)/(maximum possible score−minimum 
possible), where the ‘obtained score’ is the sum of the 
appraisers scores per each item, making it possible to 
consider the natural discrepancies between the two 
appraisers.
Although the domain scores are useful for comparing 
guidelines and attest whether a guideline should be 
recommended for use, the AGREE II instrument does not 
set minimum domain scores or patterns of scores across 
domains to differentiate between high quality and poor 
quality guidelines. These decisions should be made by the 
users and guided by the context in which AGREE II is 
being used.23 Then, as reported in previous studies,24 25we 
considered a value >60% as sufficient quality score and a 
value >80% as a good quality score.
On completing the 23 items, the appraisers provided 
the overall assessment of each guideline, and decided 
which guideline was recommendable, with or without 
modifications, and which was not recommendable. This 
choice was the result of the six domains’ scores and of 
the personal judgement of the appraisers. To resolve 
discrepancies between the two assessors, a method was 
used from a previous study: if the scores assigned by the 
assessors differed by 1 point the lower score was used; if 
they differed by 2 points they were averaged; and if they 
varied by ≥3 points a consensus was reached after a discus-
sion.24 25 We decided to recommend without modification 
the guidelines with an overall score equal to 7, to recom-
mend with modification the guidelines with an overall 
score ≥4 but <7, and not to recommend the guidelines 
with an overall score ≤3.
comparison of recommendations
Recommendations regarding the symptomatic manage-
ment of fever in children, reported in the selected 
guidelines, have been extracted and summarised in 




A total of 122 records were initially identified, of which, 
after screening titles and abstracts, 97 were excluded 
because they were irrelevant or duplicates. The remaining 
25 records were retrieved for full text.2 26–49 Among 
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Figure 1 Flow chart of searching and selecting guidelines.
not guidelines26 28 29 31–38 40–42 or they were not medical 
societies’ or health government guidelines39 43 46 ; one of 
the guidelines was excluded because the original publi-
cation date was before 2010.45 Finally, seven CPGs were 
selected2 27 30 44 47–49 (figure 1). The characteristics of the 
included guidelines are presented in table 1.
AGree II scores
The domain-standardised scores for selected guidelines 
and overall recommendations are presented in table 2 
and figure 2.
The American Academy of Pediatrics (AAP)2 guideline 
has good scores in clarity of presentation and editorial 
independence domains, sufficient score in scope and 
purpose, with low scores in stakeholder involvement, 
rigour of development and applicability domains.
The Italian Pediatric Society (SIP)27 guideline has 
good scores in scope and purpose, stakeholder involve-
ment, rigour of development, clarity of presentation and 
editorial independence domains with a low score in appli-
cability domain.
The South African30 guideline has good scores in scope 
and purpose and clarity of presentation, sufficient score 
in stakeholder involvement, but low scores in rigour of 
development, applicability and editorial independence 
domains.
The National Institute for Health and Care Excellence 
(NICE)44 guideline has good scores in scope and purpose, 
stakeholder involvement, rigour of development, clarity 
of presentation and applicability domains with a low score 
in editorial independence.
The New South Wales Ministry of Health (NSW)47 
guideline has a sufficient score in the scope and purpose 
domain, but low scores in all the others.
The South Australian Ministry of Health (SA)48 guide-
line has a good score in scope and purpose, a sufficient 
score in clarity of presentation domain, but low scores in 
the others.
The WHO49 guideline has good scores in scope and 
purpose, rigour of development, clarity of presentation 
and sufficient scores in stakeholder involvement, applica-
bility and editorial independence domains.
scope and purpose
The median score for the scope and purpose domain was 
85.28% (range 66.6–100%).
Most guidelines clearly described their overall objec-
tives, health questions and target populations. The NSW 
guideline has the lowest score.47
stakeholder involvement
The median score for the stakeholder involvement 
domain was 57.5% (range 33.30–83.30%). Only the 
SIP, South African, NICE, and WHO guidelines scored 
above 60% for this domain,27 30 44 49 whereas the AAP, 
NSW and SA guidelines did not consider the views and 
preferences of the target population.2 47 48 No guideline 
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AAP2 75% 41.60% 23.90% 83.30% 27.10% 83.30% 5. Recommended with 
modifications




88.80% 61.10% 31.20% 83.30% 8.30% 50% 4. Recommended with 
modifications
NICE44 100% 83.30% 98.90% 83.30% 100% 50% 7. Recommended
NSW47 66.60% 41.60% 16.00% 50% 33.30% 0% 3. Not recommended
SA48 83.30% 33.30% 14.60% 77.70% 16.60% 0% 3. Not recommended
WHO49 88.90% 61.10% 89.60% 94.40% 62.50% 67% 6.Recommended with 
modifications
AAP, American Academy of Pediatrics; NICE, National Institute for Health and Care Excellence; NSW, New South Wales Ministry of Health; 
SA, South Australian Ministry of Health; SIP, Italian Pediatric Society.
Figure 2 Standardised scores of each domain by AGREE II of guidelines—histogram.
development process. Only the SIP and NICE guide-
lines had methodology experts included in the guideline 
development group.27 44 Only in the NICE guideline were 
there health economists among the guideline authors.44
rigour of development
The median score for the rigour of development 
domain was 51.97% (range 14.60–98.90%). Only the 
SIP, NICE, and WHO guidelines scored >60% because 
they used systematic methods of searching for evidence 
and for formulating recommendations27 44 49 ; only the 
NICE and WHO CPGs clearly described methods for 
conducting external reviews44 49 ; and only the NICE and 
WHO CPGs described their procedures for updating 
guidelines.44 49
clarity of presentation
Most guidelines provided specific, unambiguous and 
easily identifiable recommendations. The median 
score for the clarity of presentation domain was 80.9% 
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Applicability
The median score for the applicability domain was 39.3% 
(8.3–100%). Only the NICE guideline scored >60%.44 
Most guidelines did not describe the facilitators and 
barriers of their applications and did not sufficiently 
consider the costs of applying their recommendations; 
only the NICE guideline involved a health economist in 
finding and analysing cost information.44Only the AAP 
and SA guidelines did not provide any tool or suggestions 
for putting the recommendations into practice.2 48
editorial independence
The median score for the editorial independence domain 
was 48.84% (0–91.6%); only the AAP, SIP and WHO CPGs 
scored >60%.2 27 49 The NWS and SA CPGs did not clearly 
provide financial support information.47 48 Although 
the WHO guideline reported the funding source, it 
did not specify the possible funding influence on the 
CPG content.49 Moreover, only the AAP, SIP and WHO 
guidelines include a conflict of interest statement by 
the guideline development group.2 27 49
Overall assessment
Based on the six domain scores and on a personal judge-
ment, the AAP, SIP, South African and WHO guidelines 
were recommended with modifications,2 27 30 49 only the 
NICE CPG was recommended without modifications,44 
and the NSW and SA CPGs were not recommended.47 48
summary of recommendations
Specific recommendations have been identified and 
summarised in table 3, as well as common and discordant 
messages.
common messages
1. Antipyretics are indicated only in cases of discomfort 
associated with fever and not with the sole aim of 
reducing body temperature.
2. Recommended antipyretics are paracetamol or 
ibuprofen, according to the child’s age, weight and 
characteristics.
3. The use of antipyretics does not prevent either febrile 
convulsions or reactions to vaccines.
4. Tepid sponging and alcoholic baths are not 
recommended for the treatment of fever.
5. The use of cough and cold medicine is discouraged 
because of the risks of overdoses and interactions.
6. Caution is recommended using antipyretics in 
chronic diseases such as pre-existing hepatic and renal 
impairment or in cases of diabetes, cardiac disease 
and severe malnutrition.
7. In asthmatic children with fever, paracetamol does 
not seem to worsen asthma symptoms.
Divergent messages
1. The physical method of unwrapping/uncovering 
children with fever is contraindicated by the SIP, 
South African and NICE CPGs25 28 42 and indicated 
by the NWS and WHO CPGs.47 49
2. The alternate use of two antipyretics is discouraged 
by most of the guidelines with the exception of the 
NICE and SA CPGs.44 48 These two guidelines permit 
the alternate use only if the discomfort persists after 
the administration of one antipyretic.44 48
3. The minimum age for administering paracetamol 
varies from birth (SIP, NWS, SA27 47 48) to 2 months 
(WHO49), to 3 months (South African30) (online 
supplementary file 2).
4. The posology of paracetamol varies in terms of 
dosage per single administration (10–15 or 15 mg/
kg/dose), of intervals between doses (4 hour, 
4–6 hour or 6 hour) and of maximum allowable daily 
dosage that ranges from 60 mg/kg/day to 90 mg/kg/
day (online supplementary file 2).
5. The posology of paracetamol in newborns27 48 varies 
by paracetamol dosage per single administration and 
maximum daily dosages in newborns (online 
supplementary file 3).
6. The minimum age for ibuprofen administration 
ranges from 2 to 3 months (NWS,47 WHO49) to 6 
months (AAP2) (online supplementary file 4).
7. The posology of ibuprofen is divergent in terms of 
dosage per single administration (5–10 or 10 mg/kg/
dose), of intervals between doses (6, 6–8 hours) and 
maximum daily dosage of 40 mg for all guidelines 
except the SIP CPG that allows up to 30 mg27(online 
supplementary file 4).
8. The use of ibuprofen in asthmatic patients is 
contraindicated in the SIP CPG only in patients with 
asthma related to non-steroidal anti-inflammatory 
drugs but indicated with caution in all asthmatic 
patients by the South African and SA CPGs.30 48
9. The use of ibuprofen in children with dehydration is 
contraindicated by the SIP CPG,27 but recommended 
with caution by the AAP, South African and SA 
CPGs.2 30 48
10. The use of ibuprofen in the case of varicella is 
contraindicated by the SIP CPG27 and advised with 
caution by the AAP and South African CPGs.2 30
Discussion anD conclusions
In the present study a systematic search of the avail-
able national guidelines regarding the management of 
fever in children was performed, and key messages have 
been summarised. Overall, only seven guidelines were 
retrieved, which is less than expected considering that 
fever represents a large part of the practice of healthcare 
professionals, and how common the use of these drugs is. 
In particular, only two guidelines (AAP, SIP2 27) focused 
specifically on the symptomatic management of feverish 
children, whereas the other five guidelines dealt with the 
other aspects of fever management, including aetiolog-
ical diagnosis and therapy.
Considering the impact of the quality of the guidelines 
in their application, we appraised the quality scores of the 
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Interestingly, lower quality scores were observed in the 
domains of methodology, applicability and editorial inde-
pendence, whereas all the guidelines had moderate to 
high scores in the purpose and objective and the clarity of 
the recommendations. The methodology analysis showed 
acceptable results only for the SIP,27 NICE,44 and WHO 
guidelines49 whereas the AAP,2 South African,30 NWS47 
and SA guidelines48 had insufficient scores because they 
were not based on a systematic review of the literature 
and they did not provide recommendations explicitly 
linked to evidence, or because they did not involve all the 
required members in the guideline development group.
Regarding the ‘applicability’ item, most guidelines did 
not describe the facilitators and barriers to their applica-
tion and did not provide audit criteria. Some CPGs lacked 
a summary document, and educational tools.2 30 This 
finding is in contrast with the need for clarity and user 
friendliness suggested by some authors19–22 and should 
be taken into consideration when developing new guide-
lines. Information on editorial independence was also 
neglected in most guidelines.30 44 47 48 Indeed only AAP, 
SIP and WHO guidelines reported detailed information 
on potential conflicts of interest.2 27 49 This is particularly 
important considering that conflicts of interest are the 
most common source of bias in guideline development.49 
One strength of our study is that we used the AGREE II 
instrument for the first time to assess the methodological 
quality of guidelines related to fever in children.
The AGREE II instrument is a tool that assesses the meth-
odological rigour and transparency with which a guideline 
is developed.23 A potential limitation of this method is that 
there is no threshold for distinguishing between high quality 
and low quality CPGs. Thus, the guideline quality would be 
left to the appraisers to identify and the scores of an AGREE 
II evaluation have to be interpreted with caution and 
confined to a particular situation. Furthermore, AGREE II 
does not consider the relative importance of the six domains 
of quality: rigour of development is considered of equal 
importance to the other five domains.24 This suggests that 
the domains of AGREE II should not be weighed equally. 
If the guideline has a low score on the domain of rigour of 
development, the corresponding recommendations have a 
high risk of bias, and the other domains are of little rele-
vance in quality assessment. Another possible limitation of 
our study is that some guidelines may have been missed by 
our research.
From a comparison of the recommendations we 
observe that the guidelines agree on some crucial 
aspects. In particular, all guidelines agree on prescribing 
antipyretics only with the aim of relieving the child’s 
discomfort caused by fever and not with the sole aim of 
reducing body temperature. There is also an agreement 
on the type of recommended antipyretics which are parac-
etamol or ibuprofen, according to a child's age, weight 
and characteristics. Several studies demonstrated the 
high tolerability of both these drugs with similar efficacy 
in reducing body temperature.7 9 However, few data are 
available regarding the impact of antipyretics in reducing 
the child’s discomfort.7 9 The concept of ‘discomfort’ is 
not easy to define because it varies across different age 
groups, and may be influenced by the caregiver’s percep-
tion. Therefore, future research needs to define child 
discomfort more precisely, and how to measure it using 
standardised clinical scores.
On the other hand, some messages diverge, either 
about the use of physical methods or the pharmacolog-
ical approach. The common physical method to unwrap/
uncover children with fever is contraindicated by the SIP, 
South African and NICE CPGs,27 30 44 but it is considered 
in the NWS and WHO CPGs.47 49 Furthermore, most 
guidelines discourage the alternate/combined use of two 
antipyretics except the NICE and SA CPGs that allow the 
alternate use of the two drugs, only when distress persists 
after the administration of one antipyretic.44 48 Alternate 
use can be associated with better control of body tempera-
ture, but no study demonstrated superiority in terms of 
distress control compared with monotherapy. However, 
it is certain that alternating two drugs increases the risk 
of overdose and toxicity.9 A greater consensus from the 
international scientific community would be desirable on 
a topic of such wide resonance.
In conclusion, most guidelines issued at national or 
international levels were of good quality and could be 
adopted in clinical practice. Nevertheless, the quality 
of the CPGs could be improved, in particular the meth-
odological, applicability and editorial independence 
domains. Our study reinforces the messages of concor-
dant recommendations and shines a light on discordant 
suggestions, and could stimulate the issues of interna-
tional guidelines in order to unify medical behaviour.
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